

Supplementary Data:

Novel Pharmacological Treatment Options in Pediatric Glioblastoma—A Systematic Review

Johanna Wyss ^{1,2,*}, Nicole Alexandra Frank ^{3,†}, Jehuda Soleman ^{3,4,5,†} and Katrin Scheinemann ^{1,6,7,†}

Table S1. Predefined parameters according to PICO for evidence-based medicine.

Population	Intervention	Comparison	Outcome
Pediatric patients with GBM; age 0–18 years	Pharmacological treatment other than monotherapy with TMZ	No comparison (NA)	OS; PFS; EFS

GBM = glioblastoma, TMZ = temozolomide, NA = not applicable, OS = overall survival, PFS = progression free survival, EFS = event free survival.